ATE523504T1 - 1-thio-d-glucitolderivate - Google Patents

1-thio-d-glucitolderivate

Info

Publication number
ATE523504T1
ATE523504T1 AT06711505T AT06711505T ATE523504T1 AT E523504 T1 ATE523504 T1 AT E523504T1 AT 06711505 T AT06711505 T AT 06711505T AT 06711505 T AT06711505 T AT 06711505T AT E523504 T1 ATE523504 T1 AT E523504T1
Authority
AT
Austria
Prior art keywords
compound
thio
glucitol
pharmaceutical
provides
Prior art date
Application number
AT06711505T
Other languages
English (en)
Inventor
Hiroyuki Kakinuma
Yuko Hashimoto
Takahiro Oi
Hitomi Takahashi
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36647674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE523504(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE523504T1 publication Critical patent/ATE523504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06711505T 2005-01-07 2006-01-10 1-thio-d-glucitolderivate ATE523504T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005002913 2005-01-07
JP2005233912 2005-08-12
PCT/JP2006/300135 WO2006073197A1 (ja) 2005-01-07 2006-01-10 １－チオ－d－グルシトール誘導体

Publications (1)

Publication Number Publication Date
ATE523504T1 true ATE523504T1 (de) 2011-09-15

Family

ID=36647674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06711505T ATE523504T1 (de) 2005-01-07 2006-01-10 1-thio-d-glucitolderivate

Country Status (24)

Country Link
US (2) US7910619B2 (de)
EP (1) EP1845095B1 (de)
JP (2) JP4492968B2 (de)
KR (1) KR101268752B1 (de)
CN (1) CN101103013B (de)
AT (1) ATE523504T1 (de)
AU (1) AU2006204258C1 (de)
BR (1) BRPI0606397B8 (de)
CA (1) CA2592995C (de)
CY (1) CY1112467T1 (de)
DK (1) DK1845095T3 (de)
ES (1) ES2369030T3 (de)
HR (1) HRP20110791T1 (de)
ME (1) ME01324B (de)
MX (1) MX2007008285A (de)
NO (1) NO341129B1 (de)
NZ (1) NZ556342A (de)
PL (1) PL1845095T3 (de)
PT (1) PT1845095E (de)
RS (1) RS52066B (de)
SI (1) SI1845095T1 (de)
TW (1) TW200637839A (de)
WO (1) WO2006073197A1 (de)
ZA (1) ZA200706021B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2076503B1 (de) * 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenylglycitolverbindung zur behandlung von diabetes
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2036901B1 (de) 2006-06-29 2013-05-01 Taisho Pharmaceutical Co., Ltd C-phenyl-1-thioglucitverbindung
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN101522699A (zh) * 2006-10-13 2009-09-02 中外制药株式会社 硫葡萄糖螺缩酮衍生物、及其作为糖尿病治疗药的应用
AU2007332476A1 (en) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
KR101100072B1 (ko) * 2006-12-21 2011-12-29 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체의 제조방법 및 이의 합성 중간체
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN104803957A (zh) * 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2187742T (pt) 2007-08-23 2018-01-04 Theracos Sub Llc Derivados de (2s,3r,4r,5s,6r)-2-(4-cloro-3-benzilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol para utilização no tratamento da diabetes
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
JP2009107997A (ja) * 2007-10-31 2009-05-21 Taisho Pharmaceutical Co Ltd （１ｓ）−１，５−アンヒドロ−１−［５−（４−エトキシベンジル）−２−メトキシ−４−メチルフェニル］−１−チオ−ｄ−グルシトールの結晶形とその製造方法
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CA2725047A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
MY155418A (en) * 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP2010180143A (ja) * 2009-02-03 2010-08-19 Taisho Pharmaceutical Co Ltd ４−（置換ベンジル）−２−ハロフェノール誘導体の製造法
AU2014221222B2 (en) * 2009-04-16 2016-04-28 Taisho Pharmaceutical Co., Ltd. Pharmaceutical compositions
PL2601949T3 (pl) * 2009-04-16 2015-04-30 Taisho Pharmaceutical Co Ltd Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
LT2488515T (lt) 2009-10-14 2017-03-10 Janssen Pharmaceutica Nv Junginių, naudotinų kaip sglt2 inhibitorių, paruošimo būdas
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2568988B1 (de) 2010-05-11 2016-07-13 Janssen Pharmaceutica, N.V. Pharmazeutische zubereitungen enthaltend 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzol derivate mit sglt inhibitorischer wirkung
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5973551B2 (ja) 2011-04-13 2016-08-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN103596564B (zh) * 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
SG11201406080VA (en) 2012-03-28 2014-11-27 Fujifilm Corp SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013152476A1 (en) * 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
HUE044412T2 (hu) 2012-08-13 2019-10-28 Fujifilm Corp Intermedier l-(2-deoxi-2-fluor-4-tio-beta-D-arabinofuranozil)-citozin szintézisére, intermedier tionukleozid szintézisére és eljárások ezen intermedierek elõállítására
AU2013309904A1 (en) * 2012-08-30 2015-03-19 Taisho Pharmaceutical Co., Ltd. Combinations of SGLT 2 inhibitors and antihypertensive drugs
CN103864737B (zh) * 2012-12-17 2016-08-17 天津药物研究院 含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
EP3246324B1 (de) * 2012-12-17 2021-08-25 Tianjin Institute of Pharmaceutical Research Phenyl-c-glucosid-derivat mit einer deoxyglucosestruktur, herstellungsverfahren dafür und verwendungen davon
CA2923522C (en) * 2013-09-09 2018-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. C-aryl glucoside derivative, preparation method for same, and medical applications thereof
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
CN106061959B (zh) 2014-02-18 2018-11-09 富士胶片株式会社 四氢噻吩骨架型糖化合物的制造方法及四氢噻吩骨架型糖化合物
JP6204223B2 (ja) * 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
EP3508205B1 (de) 2016-08-31 2022-05-18 FUJIFILM Corporation Antitumormittel, antitumoreffektverstärker und antitumorkit
JP2019531320A (ja) 2016-10-19 2019-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｓａｏ／ｖａｐ−１阻害剤とｓｇｌｔ２阻害剤とを含む組合せ、その使用
KR101943382B1 (ko) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN107857753A (zh) * 2017-12-04 2018-03-30 威海贯标信息科技有限公司 一种鲁格列净新晶型
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
EP3781166A1 (de) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzung, verfahren zur behandlung und verwendungen davon
CN112739365B (zh) 2018-08-10 2025-10-28 糖平制药公司 三肽以及代谢、心血管和炎性病症的治疗
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7217875B2 (ja) * 2018-09-21 2023-02-06 国立大学法人 琉球大学 血液がんの予防及び／又は治療剤
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
ES2967359T3 (es) 2018-10-29 2024-04-29 Boehringer Ingelheim Int Derivados piridinil-sulfonamida, composiciones farmacéuticas y usos de los mismos
WO2020151621A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及医药用途
WO2020151623A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
WO2020151620A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
CN111471031B (zh) * 2019-01-24 2023-05-16 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
CN111840271B (zh) * 2019-04-25 2024-05-14 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物新用途
CN111471032B (zh) * 2019-01-24 2023-08-01 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111471040B (zh) * 2019-01-24 2023-06-02 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
BR112023003866A2 (pt) 2020-09-02 2023-04-04 Laboratorios Silanes S A De C V Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475100A1 (es) 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
US5773663A (en) * 1996-05-01 1998-06-30 American Cyanamid Company Fungicidal methods, compounds and compositions containing benzophenones
CZ294096B6 (cs) 1995-01-20 2004-10-13 Americanácyanamidácompany Benzofenonové sloučeninyŹ způsob jejich výrobyŹ fungicidní prostředky s jejich obsahem a způsob ochrany rostlin
CA2190699A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Tertiary amines
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
CN100341885C (zh) * 2002-08-09 2007-10-10 大正制药株式会社 选择性制备芳基5－硫代－β－D－吡喃己醛糖苷的方法
KR101001848B1 (ko) 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
JPWO2004089967A1 (ja) 2003-04-01 2006-07-06 大正製薬株式会社 ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
EP2036901B1 (de) * 2006-06-29 2013-05-01 Taisho Pharmaceutical Co., Ltd C-phenyl-1-thioglucitverbindung
AU2007332476A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative

Also Published As

Publication number Publication date
BRPI0606397B8 (pt) 2021-05-25
PT1845095E (pt) 2011-10-03
JP4492968B2 (ja) 2010-06-30
EP1845095B1 (de) 2011-09-07
EP1845095A4 (de) 2008-06-25
HK1112239A1 (en) 2008-08-29
NO341129B1 (no) 2017-08-28
US20080132563A1 (en) 2008-06-05
TW200637839A (en) 2006-11-01
RS52066B (sr) 2012-06-30
CA2592995A1 (en) 2006-07-13
US8017792B2 (en) 2011-09-13
CY1112467T1 (el) 2015-12-09
DK1845095T3 (da) 2011-11-21
AU2006204258B2 (en) 2011-07-07
JP2010059173A (ja) 2010-03-18
ZA200706021B (en) 2008-12-31
MX2007008285A (es) 2007-11-23
JPWO2006073197A1 (ja) 2008-08-07
BRPI0606397B1 (pt) 2020-10-13
AU2006204258C1 (en) 2011-11-17
ME01324B (me) 2013-12-20
CN101103013A (zh) 2008-01-09
BRPI0606397A (pt) 2008-03-11
US7910619B2 (en) 2011-03-22
TWI374882B (de) 2012-10-21
AU2006204258A1 (en) 2006-07-13
WO2006073197A1 (ja) 2006-07-13
ES2369030T3 (es) 2011-11-24
SI1845095T1 (sl) 2011-12-30
CN101103013B (zh) 2012-05-23
CA2592995C (en) 2012-07-10
RU2007130089A (ru) 2009-02-20
NO20074012L (no) 2007-10-08
NZ556342A (en) 2010-04-30
RU2387649C2 (ru) 2010-04-27
JP5187592B2 (ja) 2013-04-24
PL1845095T3 (pl) 2012-02-29
HRP20110791T1 (hr) 2011-11-30
AU2006204258B9 (en) 2011-08-04
KR20070098811A (ko) 2007-10-05
US20110098469A1 (en) 2011-04-28
EP1845095A1 (de) 2007-10-17
KR101268752B1 (ko) 2013-05-29

Similar Documents

Publication Publication Date Title
ATE523504T1 (de) 1-thio-d-glucitolderivate
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2006136606A3 (en) Oxindole derivatives
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008079873A3 (en) Thiazolyl compounds useful as kinase inhibitors
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006096444A3 (en) Chemical compounds
EP2077111A4 (de) Antidepressivum
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2007009724A3 (en) Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
TNSN07453A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
WO2007104933A8 (en) Chemical compounds
WO2009018551A3 (en) Therapeutic compounds
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
NO20070421L (no) Radiosensitiviserende middel
WO2009017383A3 (en) Sustained-release formulation comprising metformin acid salt
WO2005118558A3 (de) Pyrimidinverbindungen und ihre verwendung
WO2008050698A3 (en) Agent for prophylaxis or treatment of alcohol dependence or drug dependence
NO20063860L (no) 7-fenylamino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav samt deres anvendelse som legemidler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1845095

Country of ref document: EP